Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT07758621Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Sep 2028
01
Overview
Phase 3, randomised, open-label trial of CPO301 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Objective Response Rate as assessed by IRC and Overall Survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07758621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758621.